• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form S-3/A filed by Femasys Inc.

    12/4/25 5:27:38 PM ET
    $FEMY
    Medical/Dental Instruments
    Health Care
    Get the next $FEMY alert in real time by email
    S-3/A 1 ny20060046x2_s3a.htm S-3/A
    As filed with the Securities and Exchange Commission on December 4, 2025
    Registration No. 333-288527
    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
    Pre-Effective Amendment No. 1
    FORM S-3
    REGISTRATION STATEMENT
    UNDER
    THE SECURITIES ACT OF 1933
    Femasys Inc.
    (Exact name of registrant as specified in its charter)
     
     
     
     
    Delaware
     
     
    11-3713499
    (State or other jurisdiction of
    incorporation or organization)
     
     
    (I.R.S. Employer
    Identification Number)
     
     
     
     
    3950 Johns Creek Court, Suite 100
    Suwanee, Georgia 30024
    (770) 500-3910
    (Address, including zip code, and telephone number, including area code of registrant’s principal executive offices)
    Kathy Lee-Sepsick
    President and Chief Executive Officer
    3950 Johns Creek Court, Suite 100
    Suwanee, Georgia 30024
    (770) 500-3910
    (Name, address, including zip code, and telephone number, including area code, of agent for service)
    Copies to:
    David S. Rosenthal, Esq.
    Anna Tomczyk, Esq.
    Dechert LLP
    1095 Avenue of the Americas
    New York, New York 10036
    Approximate date of commencement of proposed sale to the public: From time to time after the effective date of this Registration Statement.
    If the only securities being registered on this Form are being offered pursuant to dividend or interest reinvestment plans, please check the following box:  ☐
    If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, other than securities offered only in connection with dividend or interest reinvestment plans, check the following box: ☒
    If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering:  ☐
    If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earliest effective registration statement for the same offering:  ☐
    If this Form is a registration statement pursuant to General Instruction I.D. or a post-effective amendment thereto that shall become effective upon filing with the Commission pursuant to Rule 462(e) under the -Securities Act, check the following box.  ☐
    If this Form is a post-effective amendment to a registration statement filed pursuant to General Instruction I. D. filed to register additional securities or additional classes of securities pursuant to Rule 413(b) under the Securities Act, check the following box.  ☐
    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act. (Check one):
     
     
     
     
     
     
     
     
     
     
    Large accelerated filer
     
     
     ☐
     
     
    Accelerated filer
     
     
     ☐
    Non-accelerated filer
     
     
    ☒
     
     
    Smaller reporting company
     
     
    ☒
    Emerging growth company
     
     
    ☒
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☒
    The Registrant hereby amends this registration statement on such date or dates as may be necessary to delay its effective date until the Registrant shall file a further amendment which specifically states that this registration statement shall thereafter become effective in accordance with Section 8(a) of the Securities Act of 1933, as amended, or until the registration statement shall become effective on such date as the Commission, acting pursuant to said Section 8(a), may determine.

    EXPLANATORY NOTE
    This Amendment No. 1 (this “Amendment”) to the Registration Statement on Form S-3 (File No. 333- 288527) originally filed on July 3, 2025 (the “Registration Statement”), is being filed solely for the purpose of replacing the Exhibit 23.1 consent of independent registered public accounting firm (the “Auditor’s Consent”) previously filed with the Registration Statement with the Exhibit 23.1 Auditor’s Consent filed herewith. Accordingly, this Amendment consists only of the cover page, this explanatory note, Part II of the Registration Statement and the Auditor’s consent filed herewith as Exhibit 23.1. This Amendment does not modify any other part of the Registration Statement.

    PART II
     
    INFORMATION NOT REQUIRED IN THE PROSPECTUS
    Item 14.
    Other Expenses of Issuance and Distribution
    The following table sets forth the estimated costs and expenses, other than underwriting discounts and commissions, payable by us in connection with the offering of the securities being registered. All the amounts shown are estimates, except for the SEC registration fee and FINRA filing fee.
     
     
     
     
    SEC registration fee
     
     
    $22,965
    FINRA filing fee
     
     
    $23,000
    Accounting fees and expenses
     
     
    *
    Legal fees and expenses
     
     
    *
    Transfer agent fees and expenses
     
     
    *
    Trustee fees and expenses
     
     
    *
    Printing and miscellaneous expenses
     
     
    *
    Total
     
     
    $*
     
     
     
     
    *
    These fees cannot be estimated at this time, as they are calculated based on the securities offered and the number of issuances. In accordance with Rule 430B, an estimate of the aggregate expenses in connection with the sale and distribution of the securities being offered will be included in the applicable prospectus supplement
    II-1

    Item 15.
    Indemnification of Officers and Directors
    The Registrant is governed by the Delaware General Corporation Law, or DGCL. Section 145 of the DGCL provides that a corporation may indemnify any person, including an officer or director, who was or is, or is threatened to be made, a party to any threatened, pending or completed legal action, suit or proceeding, whether civil, criminal, administrative or investigative (other than an action by or in the right of such corporation), by reason of the fact that such person was or is an officer, director, employee or agent of such corporation or is or was serving at the request of such corporation as a director, officer, employee or agent of another corporation or enterprise. The indemnity may include expenses (including attorneys' fees), judgments, fines and amounts paid in settlement actually and reasonably incurred by such person in connection with such action, suit or proceeding, provided such officer, director, employee or agent acted in good faith and in a manner such person reasonably believed to be in, or not opposed to, the corporation's best interest and, for criminal proceedings, had no reasonable cause to believe that such person's conduct was unlawful. A Delaware corporation may indemnify any person, including an officer or director, who was or is, or is threatened to be made, a party to any threatened, pending or contemplated action or suit by or in the right of such corporation, under the same conditions, except that such indemnification is limited to expenses (including attorneys' fees) actually and reasonably incurred by such person, and except that no indemnification is permitted without judicial approval if such person is adjudged to be liable to such corporation. Where an officer or director of a corporation is successful, on the merits or otherwise, in the defense of any action, suit or proceeding referred to above, or any claim, issue or matter therein, the corporation must indemnify that person against the expenses (including attorneys' fees) which such officer or director actually and reasonably incurred in connection therewith.
    The Registrant's amended and restated bylaws authorize the indemnification of its officers and directors, consistent with Section 145 of the DGCL.
    Reference is made to Section 102(b)(7) of the DGCL, which enables a corporation in its original certificate of incorporation or an amendment thereto to eliminate or limit the personal liability of a director for violations of the director's fiduciary duty, except (i) for any breach of the director's duty of loyalty to the corporation or its stockholders, (ii) for acts or omissions not in good faith or which involve intentional misconduct or a knowing violation of law, (iii) pursuant to Section 174 of the DGCL, which provides for liability of directors for unlawful payments of dividends of unlawful stock purchase or redemptions or (iv) for any transaction from which a director derived an improper personal benefit.
    We have entered into indemnification agreements with each of our directors and officers. These indemnification agreements may require us, among other things, to indemnify our directors and officers for some expenses, including attorneys' fees, judgments, fines and settlement amounts incurred by a director or officer in any action or proceeding arising out of his or her service as one of our directors or officers, or any of our subsidiaries or any other company or enterprise to which the person provides services at our request.
    We maintain a general liability insurance policy that covers certain liabilities of directors and officers of our corporation arising out of claims based on acts or omissions in their capacities as directors or officers.
    In any underwriting agreement we enter into in connection with the sale of securities being registered hereby, the underwriters will agree to indemnify, under certain conditions, us, our directors and officers (as well as certain other persons) against certain liabilities arising in connection with such offering.
    Insofar as the forgoing provisions permit indemnification of directors, executive officers, or persons controlling us for liability arising under the Securities Act of 1933, as amended, or the Securities Act, we have been informed that, in the opinion of the SEC, such indemnification is against public policy as expressed in the Securities Act and is therefore unenforceable.
    II-2

    Item 16.
    Exhibits and Financial Statement Schedules
    EXHIBIT INDEX
     
     
     
     
    Exhibit Number
     
     
    Description
    of Document
    1.1*
     
     
    Form of Underwriting Agreement
    3.1**
     
     
    Eleventh Amended and Restated Certificate of Incorporation of Femasys Inc., dated as of June 22, 2021 (filed as Exhibit 3.3 to the Registration Statement on Form S-1/A of the Company (File No. 333-256156), as filed on June 14, 2021, and incorporated by reference herein).
    3.2**
     
     
    Amended and Restated Bylaws of Femasys Inc. (filed as Exhibit 3.4 to the Registration Statement on Form S-1 of the Company (File No. 333-256156), as filed on May 14, 2021, and incorporated by reference herein).
    3.3**
     
     
    First Amendment to the Amended and Restated Bylaws of Femasys Inc., dated as of March 29, 2023 (filed as Exhibit 3.1 to the Current Report on Form 8-K of the Company (File No. 001-40492), as filed on March 30, 2023, and incorporated by reference herein).
    4.1**
     
     
    Form of Common Stock Certificate of Femasys Inc. (filed as Exhibit 4.1 to the Registration Statement on Form S-1 of the Company (File No. 333-256156), as filed on May 14, 2021, and incorporated by reference herein).
    4.2*
     
     
    Form of certificate of designation with respect to any preferred stock issued hereunder and the related form of preferred stock certificate
    4.3**
     
     
    Form of indenture to be entered into between registrant and a trustee acceptable to the registrant.
    4.4*
     
     
    Form of warrant agreement.
    4.5*
     
     
    Form of warrant certificate.
    4.6*
     
     
    Form of debt security.
    4.7*
     
     
    Form of rights certificate.
    4.8*
     
     
    Form of unit agreement.
    4.9*
     
     
    Form of unit certificate.
    5.1**
     
     
    Opinion of Dechert LLP.
    23.1
     
     
    Consent of KPMG LLP.
    23.2**
     
     
    Consent of Dechert LLP (included in its Opinion filed as Exhibit 5.1 hereto).
    24.1**
     
     
    Powers of Attorney (included on signature page).
    25.1***
     
     
    Statement of Eligibility of Trustee under the Indenture.
    107**
     
     
    Filing Fee Table
     
     
     
     
    *
    To be filed, if applicable, by amendment or as an exhibit to a document filed under the Securities Exchange Act of 1934, as amended, and incorporated by reference herein.
    **
    Previously filed
    ***
    To be filed separately pursuant to Section 305(b)(2) of the Trust Indenture Act of 1939, as amended, and the appropriate rules and regulations thereunder.
    Item 17.
    Undertakings
    The undersigned registrant hereby undertakes:
    (1)
    To file, during any period in which offers or sales are being made, a post-effective amendment to this registration statement:
    (i)
    To include any prospectus required by Section 10(a)(3) of the Securities Act;
    (ii)
    To reflect in the prospectus any facts or events arising after the effective date of the registration statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the registration statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the SEC pursuant to Rule 424(b) if, in the aggregate, the
    II-3

    changes in volume and price represent no more than 20 percent change in the maximum aggregate offering price set forth in the “Calculation of Registration Fee” table in the effective registration statement; and
    (iii)
    To include any material information with respect to the plan of distribution not previously disclosed in the registration statement or any material change to such information in the registration statement;
    provided, however, that the undertakings set forth in paragraphs (1)(i), (1)(ii) and (1)(iii) above do not apply if the information required to be included in a post-effective amendment by those paragraphs is contained in reports filed with or furnished to the SEC by the registrant pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934, as amended, or the Exchange Act, that are incorporated by reference in this registration statement or are contained in a form of prospectus filed pursuant to Rule 424(b) that is part of this registration statement.
    (2)
    That, for the purpose of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.
    (3)
    To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.
    (4)
    That, for the purpose of determining liability under the Securities Act to any purchaser:
    (i)
    Each prospectus filed by the registrant pursuant to Rule 424(b)(3) shall be deemed to be part of the registration statement as of the date the filed prospectus was deemed part of and included in the registration statement; and
    (ii)
    Each prospectus required to be filed pursuant to Rule 424(b)(2), (b)(5), or (b)(7) as part of a registration statement in reliance on Rule 430B relating to an offering made pursuant to Rule 415(a)(1)(i), (vii), or (x) for the purpose of providing the information required by Section 10(a) of the Securities Act shall be deemed to be part of and included in the registration statement as of the earlier of the date such form of prospectus is first used after effectiveness or the date of the first contract of sale of securities in the offering described in the prospectus. As provided in Rule 430B, for liability purposes of the issuer and any person that is at that date an underwriter, such date shall be deemed to be a new effective date of the registration statement relating to the securities in the registration statement to which that prospectus relates, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof. Provided, however, that no statement made in a registration statement or prospectus that is part of the registration statement or made in a document incorporated or deemed incorporated by reference into the registration statement or prospectus that is part of the registration statement will, as to a purchaser with a time of contract of sale prior to such effective date, supersede or modify any statement that was made in the registration statement or prospectus that was part of the registration statement or made in any such document immediately prior to such effective date.
    (5)
    That, for the purpose of determining liability of the registrant under the Securities Act to any purchaser in the initial distribution of the securities, the undersigned registrant undertakes that in a primary offering of securities of the undersigned registrant pursuant to this registration statement, regardless of the underwriting method used to sell the securities to the purchaser, if the securities are offered or sold to such purchaser by means of any of the following communications, the undersigned registrant will be a seller to the purchaser and will be considered to offer or sell such securities to such purchaser: (i) any preliminary prospectus or prospectus of the undersigned registrant relating to the offering required to be filed pursuant to Rule 424; (ii) any free writing prospectus relating to the offering prepared by or on behalf of the undersigned registrant or used or referred to by the undersigned registrant; (iii) the portion of any other free writing prospectus relating to the offering containing material information about the undersigned registrant or its securities provided by or on behalf of the undersigned registrant; and (iv) any other communication that is an offer in the offering made by the undersigned registrant to the purchaser.
    II-4

    (6)
    That, for purposes of determining any liability under the Securities Act, each filing of the registrant’s annual report pursuant to Section 13(a) or 15(d) of the Exchange Act (and, where applicable, each filing of an employee benefit plan’s annual report pursuant to Section 15(d) of the Exchange Act) that is incorporated by reference in the registration statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.
    (7)
    To file an application for the purpose of determining the eligibility of the trustee to act under subsection (a) of Section 310 of the Trust Indenture Act in accordance with the rules and regulations prescribed by the SEC under Section 305(b)(2) of the Trust Indenture Act.
    Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the registrant pursuant to the foregoing provisions, or otherwise, the registrant has been advised that in the opinion of the Securities and Exchange Commission such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred or paid by a director, officer or controlling person of the registrant in the successful defense of any action, suit or proceeding) is asserted against the registrant by such director, officer or controlling person in connection with the securities being registered, the registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question of whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.
    II-5

    SIGNATURES
    Pursuant to the requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-3 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Suwanee, State of Georgia, on the 4th day of December, 2025.
     
     
     
     
    FEMASYS INC.
     
     
     
     
     
     
     
     
     
     
    By:
     
     
    /s/ Kathy Lee-Sepsick
     
     
     
     
     
     
    Kathy Lee-Sepsick
     
     
     
     
     
     
    Chief Executive Officer and President
     
     
     
     
     
     
     
     
     
     
    II-6

    Pursuant to the requirements of the Securities Act of 1933, this registration statement has been signed by the following persons in the capacities and on the dates indicated.
     
     
     
     
     
     
     
    Name and Signature
     
     
    Title
     
     
    Date
     
     
     
     
     
     
     
    /s/ Kathy Lee-Sepsick
     
     
    President and Chief Executive Officer and
    Member of the Board of Directors (Principal Executive Officer)
     
     
    December 4, 2025
    Kathy Lee-Sepsick
     
     
     
     
     
     
     
     
    /s/ Dov Elefant
     
     
    Chief Financial Officer
    (Principal Financial and Accounting Officer)
     
     
    December 4, 2025
    Dov Elefant
     
     
     
     
     
     
     
     
    *
     
     
    Director
     
     
    December 4, 2025
    Charles Larsen
     
     
     
     
     
     
     
     
    *
     
     
    Director
     
     
    December 4, 2025
    Alistair Milnes
     
     
     
     
     
     
     
     
     
     
     
    Director
     
     
    December 4, 2025
    Joshua Silverman
     
     
     
     
     
     
     
     
    *
     
     
    Director
     
     
    December 4, 2025
    Edward Uzialko, Jr.
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
    *By:
     
     
    /s/ Kathy Lee-Sepsick
     
     
     
     
     
     
    Kathy Lee-Sepsick
     
     
     
     
     
     
    Attorney-in-fact
     
     
     
     
     
     
     
     
     
     
    II-7
    Get the next $FEMY alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $FEMY

    DatePrice TargetRatingAnalyst
    11/20/2025$6.50Buy
    Laidlaw
    7/13/2021$18.00Buy
    JonesTrading
    7/13/2021$25.00Buy
    Chardan Capital
    More analyst ratings

    $FEMY
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Chief Executive Officer Lee-Sepsick Kathy

    4 - FEMASYS INC (0001339005) (Issuer)

    11/19/25 4:05:14 PM ET
    $FEMY
    Medical/Dental Instruments
    Health Care

    SEC Form 4 filed by Director Larsen Charles

    4 - FEMASYS INC (0001339005) (Issuer)

    11/12/25 5:27:57 PM ET
    $FEMY
    Medical/Dental Instruments
    Health Care

    SEC Form 4 filed by Chief Financial Officer Elefant Dov

    4 - FEMASYS INC (0001339005) (Issuer)

    11/12/25 5:23:57 PM ET
    $FEMY
    Medical/Dental Instruments
    Health Care

    $FEMY
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    PharmaCyte Biotech Successfully Monetizes Femasys Stake, Strengthening Cash Position and Underscoring Strategic Capital Deployment

    PharmaCyte Biotech, Inc. (NASDAQ:PMCB) ("PharmaCyte" or the "Company"), today announced the successful monetization of its stake in Femasys Inc. (NASDAQ:FEMY), further validating the Company's strategic approach to capital deployment and strengthening its already solid financial position. Following the monetization of the stake, PharmaCyte's cash and marketable securities are expected to increase to approximately $20 million, up from $13.3 million as of July 31, 2025. This transaction highlights the Company's ability to identify and execute on high-quality opportunities that deliver strong returns while maintaining a conservative risk profile. "Our successful monetization of the Femasys p

    11/25/25 9:15:00 AM ET
    $FEMY
    $PMCB
    Medical/Dental Instruments
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    Femasys Announces Third Quarter Financial Results for 2025

    – FDA Approval to Advance Final FemBloc® Trial with Clear Pathway to Potentially Achieve U.S. FDA Approval – – $12 Million Financing Strengthens Balance Sheet and Extends Cash Runway – ATLANTA, Nov. 14, 2025 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ:FEMY), a leading biomedical innovator making fertility and non-surgical permanent birth control more accessible and cost-effective to women worldwide, announced its financial results for the third quarter of 2025. Corporate Highlights from 3Q 2025 Announced second partner order for FemBloc in EuropeAnnounced FDA IDE approval to continue enrollment in final phase of the FINALE pivotal trial for FemBlocAnnounced a definitive agreement

    11/14/25 4:01:00 PM ET
    $FEMY
    Medical/Dental Instruments
    Health Care

    Femasys Advances Global Growth with Second Partner Order for FemBloc® in Europe

    -- Continued rollout of FemBloc, the breakthrough non-surgical permanent contraceptive solution, expands the Company's presence in key European Markets -- ATLANTA, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ:FEMY), a leading biomedical innovator making fertility and non-surgical permanent birth control more accessible and cost-effective to women worldwide, today announced a significant initial order valued at approximately $500,000 USD for the commercial launch of FemBloc Permanent Birth Control in France and the Benelux region through its partnership with leading distributor Kebomed. Following the Company's recent entry into Spain, this order marks continued progress in expand

    11/10/25 9:00:00 AM ET
    $FEMY
    Medical/Dental Instruments
    Health Care

    $FEMY
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Laidlaw initiated coverage on Femasys with a new price target

    Laidlaw initiated coverage of Femasys with a rating of Buy and set a new price target of $6.50

    11/20/25 8:06:38 AM ET
    $FEMY
    Medical/Dental Instruments
    Health Care

    JonesTrading initiated coverage on Femasys with a new price target

    JonesTrading initiated coverage of Femasys with a rating of Buy and set a new price target of $18.00

    7/13/21 11:41:28 AM ET
    $FEMY
    Medical/Dental Instruments
    Health Care

    Chardan Capital initiated coverage on Femasys with a new price target

    Chardan Capital initiated coverage of Femasys with a rating of Buy and set a new price target of $25.00

    7/13/21 8:04:59 AM ET
    $FEMY
    Medical/Dental Instruments
    Health Care

    $FEMY
    SEC Filings

    View All

    SEC Form EFFECT filed by Femasys Inc.

    EFFECT - FEMASYS INC (0001339005) (Filer)

    12/10/25 12:15:08 AM ET
    $FEMY
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form S-3/A filed by Femasys Inc.

    S-3/A - FEMASYS INC (0001339005) (Filer)

    12/4/25 5:27:38 PM ET
    $FEMY
    Medical/Dental Instruments
    Health Care

    SEC Form 10-Q filed by Femasys Inc.

    10-Q - FEMASYS INC (0001339005) (Filer)

    11/14/25 4:13:38 PM ET
    $FEMY
    Medical/Dental Instruments
    Health Care

    $FEMY
    Financials

    Live finance-specific insights

    View All

    Femasys Announces Financial Results for Quarter Ended March 31, 2025, and Provides Corporate Update

    -- Company delivers on mission to transform women's health with innovative solutions, including FemaSeed® for first-line infertility treatment and FemBloc® non-surgical permanent birth control (full system approval pending in Europe) -- ATLANTA, May 08, 2025 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ:FEMY), a leading biomedical innovator addressing significant unmet needs in women's health worldwide, with a broad portfolio of disruptive, accessible, in-office therapeutic and diagnostic products, announces financial results for the quarter ended March 31, 2025 and provides a corporate update. Corporate Highlights from 1Q 2025 to date Announced FemBloc permanent birth control delivery syste

    5/8/25 5:01:00 PM ET
    $FEMY
    Medical/Dental Instruments
    Health Care

    Femasys Announces Financial Results for Year Ended December 31, 2024, and Provides Corporate Update

    -- Company expands commercial product offering with FemBloc® permanent birth control (delivery system) approval in Europe and signed partnerships for distribution in Spain -- ATLANTA, March 27, 2025 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ:FEMY), a leading biomedical innovator addressing significant unmet needs in women's health worldwide, with a broad portfolio of disruptive, accessible, in-office therapeutic and diagnostic products, announces financial results for the year ended December 31, 2024 and provides a corporate update. Corporate Highlights from 4Q 2024 to date Announced FemBloc® permanent birth control (delivery system) approval in Europe; FemBloc blended polymer component s

    3/27/25 9:00:00 AM ET
    $FEMY
    Medical/Dental Instruments
    Health Care

    Femasys Announces Financial Results for Quarter Ended September 30, 2024, and Provides Corporate Update

    ATLANTA, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ:FEMY), a leading biomedical company focused on addressing significant unmet needs of women worldwide with a broad portfolio of in-office, accessible and innovative therapeutic and diagnostic products, announces financial results for the quarter ended September 30, 2024 and provides a corporate update. Corporate Highlights from 3Q 2024 to date Announced partnership with Boston IVF, prominent network of fertility centers, to offer FemaSeed®Announced the onboarding of the first infertility medical clinic customers to offer FemaSeed infertility treatment to patients in California and FloridaAnnounced strategic distributi

    11/12/24 8:30:00 AM ET
    $FEMY
    Medical/Dental Instruments
    Health Care

    $FEMY
    Leadership Updates

    Live Leadership Updates

    View All

    Femasys Closes $8 Million in Financing to Accelerate Commercialization of Fertility and Birth Control Portfolios

    --Existing investors, including Femasys' largest shareholders, reaffirm confidence in Femasys' strategy for growth and impact in women's health-- ATLANTA, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ:FEMY), a leading biomedical innovator making fertility and non-surgical permanent birth control more accessible and cost-effective to women worldwide, announced today the closing of $8 million in financing. This funding will provide critical resources to accelerate commercialization efforts and strengthen the company's ability to address significant unmet needs in women's reproductive health. To underscore this momentum, Femasys' largest shareholder, Jorey Chernett also provided co

    9/2/25 9:00:00 AM ET
    $FEMY
    Medical/Dental Instruments
    Health Care

    Femasys Names New Chief Commercial Officer to Drive Execution and Global Growth

    --New CCO to Lead U.S. Commercialization of Fertility Products, Including FemaSeed®, and Expand Strategic Global Partnerships Across Full Portfolio-- ATLANTA, June 17, 2025 (GLOBE NEWSWIRE) -- Femasys, Inc. (NASDAQ:FEMY), a leading biomedical innovator addressing significant unmet needs in women's health worldwide, with a broad portfolio of disruptive, accessible, in-office therapeutic and diagnostic products, today announced the appointment of Kelley Nicholas as Chief Commercial Officer (CCO). Ms. Nicholas will be responsible for leading the execution and optimization of Femasys' commercial strategy to drive revenue growth across its entire portfolio, with a particular focus on e

    6/17/25 9:00:00 AM ET
    $FEMY
    Medical/Dental Instruments
    Health Care

    Femasys Invites Investors to View Fireside Chat Today, March 21, 2024, to Discuss the Infertility Treatment Landscape

    ATLANTA, March 21, 2024 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ:FEMY), a leading biomedical company focused on addressing the significant unmet needs of women worldwide with a broad portfolio of in-office, accessible and innovative therapeutic and diagnostic products, invites investors to join management in a Fireside Chat with Jones Trading Analyst Catherine Novack to discuss the current treatment landscape for infertility treatment in women. Those interested in attending the event, which will be held virtually TODAY, March 21, 2024 at 1PM ET, may register here. Femasys CEO Kathy Lee-Sepsick and Chief Medical Officer James Liu, M.D. will focus on the current treatment options in the inf

    3/21/24 9:00:00 AM ET
    $FEMY
    Medical/Dental Instruments
    Health Care

    $FEMY
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13D filed by Femasys Inc.

    SC 13D - FEMASYS INC (0001339005) (Subject)

    11/22/23 4:00:15 PM ET
    $FEMY
    Medical/Dental Instruments
    Health Care